Study Finds Current Vaccines Neutralize Emerging SARS-CoV-2 Variant PJ.2.1
Recent laboratory research indicates that antibodies from updated COVID-19 boosters effectively neutralize the new PJ.2.1 variant, despite its enhanced ability to bind to human cells.
🧠AI AnalysisPhoto: Medical Xpress
Key points
- PJ.2.1 is an emerging saltation variant exhibiting stronger binding to the ACE2 cellular receptor.
- Laboratory tests show that antibodies from the current XFG-adapted vaccine effectively neutralize the variant.
- Researchers found no evidence that PJ.2.1 causes more severe illness or different symptoms than prior strains.
A new SARS-CoV-2 variant designated PJ.2.1, which has been spreading internationally since May, remains vulnerable to antibodies generated by the current booster vaccine, according to a recent study conducted by researchers at the German Primate Center and Hannover Medical School. The findings, published in scientific journals including the Journal of Infection and The Lancet Infectious Diseases, offer reassuring data amid high infection numbers in Europe and North America.
The research team, led by infection biologists Markus Hoffmann and Stefan Pöhlmann alongside Georg Behrens' group, investigated the biological characteristics of PJ.2.1. Their laboratory experiments revealed that the variant's spike protein binds more strongly to the ACE2 receptor compared to other studied strains, allowing it to more efficiently enter cells that express lower levels of this receptor. However, despite these enhanced cellular entry traits, tests showed that antibodies elicited by the XFG-adapted mRNA vaccine successfully inhibited the variant.
What to know: While the study suggests that current vaccination offers meaningful cross-protection against PJ.2.1, experts emphasize that virus evolution is ongoing, and future mutations could alter immune escape properties. The variant has been detected across various age groups, though current data shows no indication of elevated disease severity or novel clinical symptoms. Readers should consult a healthcare professional for guidance regarding personal vaccination choices.
Source Medical Xpress — medicalxpress.com/news/2026-11-sars-cov-variant-pj21-vaccine.html ↗
Read next
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…
🏃FitnessA Structured Approach to Beginning a Strength and Cardio Routine
A new four-week training program offers beginners a guided path to incorporating strength training and cardiovascular exercise into their daily lives.
🧠Mind & Mental HealthThe Role of Daily Mobility Training in Managing Sedentary Tension
A two-week personal trial suggests that incorporating short, daily mobility exercises may help alleviate stiffness associated with sedentary desk work. Experts note that …
🧠Mind & Mental HealthNew Theoretical Framework Explores Memory Formation and Dementia
Researchers have proposed a new model suggesting the brain's limbic system functions similarly to generative AI, potentially offering a new way to understand and classify…
🏥Public HealthRecall Issued for Generic Propranolol Over Potential Metal Contamination
Breckenridge Pharmaceutical has initiated a voluntary recall of one lot of generic propranolol capsules due to the potential presence of metal fragments.